This project aims to activate dormant follicles in patients with premature ovarian insufficiency by injecting human chorionic gonadotropin (hCG) to explore the feasibility of a treatment plan that stimulates the growth of dormant follicles, not visible to the naked eye, to antral follicles visible under ultrasound, without visible follicle growth. The project also seeks to enable patients to conceive offspring carrying their own genetic material through in vitro fertilization (IVF) technology.
Females under 40 years of age with amenorrhea or oligomenorrhea for at least four months, and elevated follicle-stimulating hormone (FSH) levels > 25 IU/l on two separate occasions (with a 4-week interval);
Ultrasound (B-mode) indicating no antral follicle development in both ovaries for at least 3 months prior to study participation;
Those who agree to participate in this study and voluntarily sign the informed consent form.
Individuals over 40 years of age, or under 40 years of age with regular menstruation, normal ovulation, amenorrhea or oligomenorrhea for less than 4 months, and elevated follicle-stimulating hormone (FSH) levels < 25 IU/l on two or more separate occasions (with a 4-week interval);
Those with contraindications to the use of injectable human chorionic gonadotropin (HCG);
Those with asthma, epilepsy, heart disease, migraines, renal impairment, hypertension, or other diseases;
Patients deemed by the researcher as otherwise unsuitable for participation in this study."
Sequential
human chorionic gonadotropin
DrugThe POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.
focilles
Bilateral ovarian follicles were monitored by ultrasound
sex hormone
chemiluminescence method
Oocyte
Stereo microscope
Embryo
Stereo microscope
Pregnancy outcome
Ultrasonic
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
